<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019106</url>
  </required_header>
  <id_info>
    <org_study_id>BITS-03</org_study_id>
    <nct_id>NCT04019106</nct_id>
  </id_info>
  <brief_title>Budesonide With Intratracheal Surfactants in Extremely Preterm Infants</brief_title>
  <acronym>BITS</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamics of Budesonide With Intratracheal Surfactant (BITS) Administration in Preterm Infants &lt; 29 Weeks Gestational Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Sciences Centre, Winnipeg, Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Boniface General Hospital Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manitoba Institute of Child Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Winnipeg Rh Institute Foundation Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BLES Biochemicals Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II trial in preterm infants aimed at identifying the optimal dose of
      budesonide with bovine lipid extract surfactant as vehicle for intratracheal administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature infants of gestational age less than 29 weeks with respiratory distress syndrome
      and clinical indication for surfactant administration will be recruited for this Phase I/II
      open-label study.

      A total of 30 subjects will be recruited from 2 neonatal intensive care units:

        1. Children's Hospital-Health Sciences Centre (HSC), Winnipeg

        2. St. Boniface General Hospital, Winnipeg, MB

      3 groups of 10 infants each will receive single dose of intratracheal budesonide (0.0625
      mg/kg, 0.125 mg/kg, and 0.25 mg/kg) with BLES surfactant (5 ml/kg). PK/PD analysis will be
      done using clinical parameters, serum biomarkers, tracheal aspirate biomarkers and plasma
      budesonide levels obtained at fixed intervals.

      The duration of subject participation will involve 12-17 weeks for the clinical intervention,
      depending on gestational age at birth and discharge date. Participants will be followed until
      40 weeks or discharge, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from serial budesonide levels</measure>
    <time_frame>At 24 hour time point following dosing</time_frame>
    <description>Blood samples will be drawn from patients to determine the serum budesonide levels to determine the area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary Dysplasia free survival</measure>
    <time_frame>at 36 weeks PMA or discharge, whichever comes first</time_frame>
    <description>NICHD criteria will be used to diagnose and grade the infants for presence of BPD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Mortality</measure>
    <time_frame>up to 40 weeks PMA or discharge, whichever comes first</time_frame>
    <description>Survival of the infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Inflammatory Biomarkers in Tracheal Aspirates</measure>
    <time_frame>Baseline, 24 hours, 48 hours,1 week, 4 weeks and 36 weeks Gestational Age</time_frame>
    <description>Tracheal aspirates will be centrifuged to isolate a large aggregate surfactant fraction that will be assayed for both phospholipid (surfactant recovery) and total protein concentration. The supernatant fraction after surfactant isolation will be assayed for total protein, and selected cytokines (IL-1 β, IL-6, IL-8, IL-10, CCL2 and TNF-ɑ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Inflammatory Biomarkers in Serum</measure>
    <time_frame>Baseline, 24 hours, 48 hours and 1 week.</time_frame>
    <description>Cytokines IL-1 β, IL-6, IL-8, IL-10, CCL2 and TNF-ɑ will be analyzed in serum samples obtained from the infants following BITS administration using commercially available ELISA kits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospital Stay</measure>
    <time_frame>from day 0 (birth date) to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VentilationStrategy</measure>
    <time_frame>till 36 weeks PMA or discharge, whichever comes first</time_frame>
    <description>Duration and modality of ventilation used in the preterm infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Severity Score</measure>
    <time_frame>at baseline and till 36 weeks PMA or discharge, whichever comes first</time_frame>
    <description>The product of Fraction of inspired oxygen and mean airway pressure will be used to estimate the respiratory severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen</measure>
    <time_frame>till 36 weeks PMA or discharge, whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Supplemental Oxygen Administered</measure>
    <time_frame>at baseline and at 36 week Post menstrual age or discharge, whichever comes first</time_frame>
    <description>the concentration of supplemental oxygen given at discharge or 36 weeks PMA compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Respiratory Support</measure>
    <time_frame>at 36 week Post menstrual age or discharge, whichever comes first</time_frame>
    <description>the presence or absence of any method of respiratory support at discharge or 36 weeks PMA compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Pulmonary Hemorrhage</measure>
    <time_frame>at baseline and 48 hours after budesonide with surfactant administration</time_frame>
    <description>Clinical signs of pallor, cyanosis, bradycardia, apnoea and blood gas changes. Radiographic evidences of patchy infiltrates to complete opacification of lung fields.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hypothalamic pituitary axis (HPA) suppression</measure>
    <time_frame>at 0 and 24 hours after dosing</time_frame>
    <description>Cortisol levels will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Pneumothorax on Chest X-ray</measure>
    <time_frame>at baseline and 48 hours after budesonide with surfactant administration</time_frame>
    <description>Identified in X-ray as hyperlucent shadow outside the lungs without pulmonary vascular markings, with or without mediastinal shift</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Spontaneous Intestinal Perforation (SIP) on abdominal X-ray</measure>
    <time_frame>at baseline and 48 hours after budesonide with surfactant administration</time_frame>
    <description>Abdominal X-ray showing presence of free air. Presence or absence of SIP will be compared across the 3 dosing groups and within the dosing groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Intra-ventricular Hemorrhage</measure>
    <time_frame>at baseline and 48 hours after budesonide with surfactant administration</time_frame>
    <description>presence or absence of will be compared across the 3 dosing groups and within the dosing groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Sepsis</measure>
    <time_frame>at baseline and till 36 weeks PMA or discharge, whichever comes first</time_frame>
    <description>As per the third international consensus definitions for sepsis and septic shock (Sepsis-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Necrotising Enterocolitis (NEC)</measure>
    <time_frame>48 hours after budesonide with surfactant administration</time_frame>
    <description>presence or absence of NEC will be compared across the 3 dosing groups and within the dosing groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Severe Retinopathy at Prematurity</measure>
    <time_frame>baseline and 48 hours after budesonide with surfactant administration</time_frame>
    <description>retinopathy of ≥grade III will be recorded</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Respiratory Distress Syndrome in Premature Infant</condition>
  <arm_group>
    <arm_group_label>Dosing Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.0625 mg/kg Budesonide in bovine lipid extract surfactant (BLES)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.125 mg/kg Budesonide in bovine lipid extract surfactant (BLES)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg/kg Budesonide in bovine lipid extract surfactant (BLES)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide in bovine lipid extract surfactant (BLES)</intervention_name>
    <description>Budesonide in bovine lipid extract surfactant</description>
    <arm_group_label>Dosing Level 1</arm_group_label>
    <arm_group_label>Dosing Level 2</arm_group_label>
    <arm_group_label>Dosing Level 3</arm_group_label>
    <other_name>Pulmicort respule</other_name>
    <other_name>BLES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female infant born between 23 and 28+6 weeks of GA

          2. Infant diagnosed with RDS according to clinical protocol criteria

          3. Able to adhere to surfactant administration protocol

          4. The patient is born in the study centre.

          5. Subject's parent(s)/legal guardian(s) has provided signed and dated informed consent
             and authorization to use protected health information, as required by national and
             local regulations.

          6. In the investigator's opinion, the subject's parent(s)/legal guardian(s) understand(s)
             and can comply with protocol requirements, instructions, and protocol-stated
             restrictions, and is likely to complete the study as planned.

        Exclusion Criteria:

          1. Older than five days at inclusion.

          2. Presence of known clinically significant congenital heart disease or other major
             congenital malformation

          3. Subjects with clinically significant laboratory abnormalities which are deemed by the
             investigator to represent a safety risk to participation in this study. Other
             laboratory parameters outside the reference range for the subject's age may be
             included if the investigator considers the abnormalities unlikely to introduce
             additional risk factors and will not interfere with data interpretation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert W 't Jong, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Research Institute of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geert W 't Jong, MD, Ph.D</last_name>
    <phone>(204)789-3206</phone>
    <email>gtjong@chrim.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abin Chandrakumar, Pharm.D, M.Sc.</last_name>
    <phone>(204)594-5359</phone>
    <email>achandrakumar@chrim.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital-Health Science Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Geert 't Jong, MD, PhD</last_name>
      <phone>2047893206</phone>
      <email>gtjong@chrim.ca</email>
    </contact>
    <contact_backup>
      <last_name>Abin Chandrakumar, PharmD, MSc</last_name>
      <phone>2045945359</phone>
      <email>achandrakumar@chrim.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Seshia, MB,BCh,FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ruben Alvaro, MD, FAAP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surfactant</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Steroid</keyword>
  <keyword>Intratracheal</keyword>
  <keyword>Preterm</keyword>
  <keyword>Bronchopulmonary Dysplasia</keyword>
  <keyword>Respiratory Distress Syndrome</keyword>
  <keyword>Bovine Lipid Extract Surfactant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

